support@mellalta.com   +1 (304) 470-2225

Digitally Optimised triple-combination asthma therapy-Latest CHMP opinion to watch

The Committee for Medicinal Products for Human Use (CHMP) supports Novartis‘ Enerzair Breezhaler, the first triple-combination asthma therapy that includes an optional digital sensor. Enerzair (formerly QVM149) consists of long-acting beta-agonist indacaterol (LABA), long-acting muscarinic […]

Read More

96.5% Adverse Events reported in mCRPC patients with Tecentriq + Xtandi Combination therapy

Researchers speculated that enzalutamide (Xtandi) could be a candidate for combination with anti-PD-1 or anti-PD-L1 agents such as Tecentriq (atezolizumab) as it “can improve IFNɣ signaling and sensitize cancer cells immune-mediated cell killing “. In […]

Read More

Adoptive TCR Therapy -A Revolution in Immuno-oncology Therapeutic Modality

Adoptive T-cell therapy is one potentially groundbreaking treatment for cancer that genetically alters natural T cells to make them tumor-specific and to improve their ability to destroy tumor cells. The genetically modified T cells are able to express chimeric […]

Read More

Coronavirus (COVID-19) Update: FDA Issues Guidance for Conducting Clinical Trials

The FDA recognizes that the COVID-19 pandemic can affect the conduct of clinical trials on medical products, including drugs, devices and biological products. Challenges may arise, for example, from quarantine, site closures, travel restrictions, supply […]

Read More

Perhaps anti-TFPI no longer a feasible strategy for Hemophilia-Novo Nordisk suspended three TFPI trials

The discovery and characterization of the anticoagulant protein factor pathway inhibitor (TFPI) has led to the realization that inhibiting TFPI activity could restore functional hemostasis through the extrinsic pathway of blood clotting in a way […]

Read More

Get In Touch

Let's keep the conversation going